Source : https://eurjmedres.biomedcentral.com/articles/10.1186/s40001-022-00716-w
Background Resistant chronic migraine is a highly disabling condition which is very difficult to treat. The majority of the treatments for migraine prophylaxis are nonspecific and present weak safety profiles,...
Conclusions: Anti-CGRP or anti-CGRP receptor monoclonal antibodies are a promising preventive migraine therapy which can be particularly useful for resistant chronic migraine patients.
Source : https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-022-01433-9
Background Clinical trials have shown that erenumab is effective and well-tolerated for the preventive treatment of chronic migraine. To extend the results from clinical trials, we assessed the real-world efficacy...
Conclusions: Among adult patients with chronic migraine and previous failure of medications for migraine prevention, erenumab was found to be effective and well-tolerated.
Saturday, June 11th was the third day of the 2022 American Headache Society Annual Scientific Meeting. Click on the image above to view highlights from our team of analysts.
Saturday, June 11th was the third day of the 2022 American Headache Society Annual Scientific Meeting. Click on the image above to view highlights from our team of analysts.
Saturday, June 11th was the third day of the 2022 American Headache Society Annual Scientific Meeting. Click on the image above to view highlights from our team of analysts.